Published Online: 2025 June 23

Brief Report



Long Intergenic Non-coding RNA – LINC00659 – Expression Changes in Gastric Cancer: Lessons from Northwestern Iran

Elmira Abdolzadeh¹, Esmat Abdi¹, Saeid Latifi-Navid ^{1,*}, Saber Zahri¹, Vahid Kholghi Oskooei², Kiana Yazdanbod³

¹ University of Mohaghegh Ardabili, Ardabil, Iran

² Sirjan School of Medical Sciences, Sirjan, Iran

³ Ardabil University of Medical Sciences, Ardabil, Iran

^{*}Corresponding Author: University of Mohaghegh Ardabili, Ardabil, Iran. Email: slatifin@yahoo.com

Received: 18 August, 2024; Revised: 9 February, 2025; Accepted: 8 June, 2025

Abstract

Background: Gastric cancer (GC) is a multifactorial disease caused by environmental, infectious, and genetic factors. Aberrant expression of long non-coding RNAs (lncRNAs) is considered a crucial feature of human cancer. They are excellent candidates as biomarkers for cancer diagnosis and prognosis, as well as potential therapeutic targets for cancer treatment.

Objectives: We assessed the expression levels of LINC00659 among GC patients in Ardabil, a high-risk region in Northwestern Iran [age-standardized incidence rates (ASRs) = 51.8/100,000 for males and 24.9/100,000 for females], which has one of the highest rates of cardia GC in the world, to examine its potential as a diagnostic biomarker.

Methods: The expression of LINC00659 in tumor and adjacent non-cancerous tissues (ANCTs) (a total of 82 samples) was evaluated using real-time qRT-PCR in Ardabil province patients. The correlation between the LINC00659 expression levels and clinicopathological features was assessed.

Results: LINC00659 was down-regulated in more GC samples than controls, but we found no significant association between the LINC00659 expression levels and GC risk between tumor samples compared to controls [fold change (mean \pm SE): 0.57 \pm 0.13, P = 0.33]. After classifying patients into down-/up-regulation groups, a significant association was observed between LINC00659 expression levels and tumor origin (cardia/non-cardia subsites; P = 0.01).

Conclusions: We found a significant association of LINC00659 expression levels with the origin of the tumor. Further research involving a larger sample size that encompasses diverse geographic and ethnic groups within Iran is essential to enhance the validity of the findings and facilitate a deeper understanding of the functional mechanisms of LINC00659 in GC.

Keywords: Gastric Cancer, LINCRNA, LINC00659, Expression Change, RT-qPCR

1. Background

Gastric cancer (GC), the fifth most common cancer, is the third leading cause of cancer-related death worldwide. In 2018, nearly 1.033 million new GC cases were diagnosed, and approximately 783,000 deaths occurred, according to GLOBOCAN estimates (1). The Cancer Genome Atlas (TCGA) project has identified four molecular subtypes of GC: Microsatellite instability (MSI), chromosomal instability (CIN), genomically stable (GS), and Epstein–Barr virus (EBV). The CIN subtype is commonly found in the esophago-gastric junction/cardia and accounts for at least 50% of GCs (2). Long non-coding RNA (lncRNA) molecules are involved in cancer and metastasis. The lncRNAs are longer than 200 nucleotides and do not translate into proteins (3). These molecules can originate from various genomic locations, including 3'- and 5'-UTRs, enhancer sequences, exon sequences, promoters, introns, and intergenic regions. The lncRNAs have various functions, including regulating gene transcription, epigenetic modification, translation, and post-transcriptional changes (4). Aberrant expression or dysfunction of lncRNAs causes many diseases. Many lncRNAs, with their tumor

Copyright © 2025, Jentashapir Journal of Cellular and Molecular Biology. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

How to Cite: Abdolzadeh E, Abdi E, Latifi-Navid S, Zahri S, Kholghi Oskooei V, et al. Long Intergenic Non-coding RNA – LINC00659 – Expression Changes in Gastric Cancer: Lessons from Northwestern Iran. Jentashapir J Cell Mol Biol. 2025; 16 (2): e153640. https://doi.org/10.5812/jjcmb-153640.

suppressor or carcinogenic effects in cancers, show irregular expression and can control cancer cell proliferation, angiogenesis, metastasis, or invasion. Due to their structural flexibility, such molecules can act as traps, signals, guides, or molecular scaffolding affecting metastasis (3, 5). The lncRNAs have been identified as novel biomarkers for the diagnosis, staging, and prognosis of GC (6). The lncRNAs have tissue-specific expression patterns and can be used to classify tumor subtypes or predict drug therapeutic effects (7, 8). Additionally, lncRNA polymorphisms (SNPs) are strongly associated with disease risk and significantly influence lncRNA expression levels (9-11).

The incidence of GC in Northwestern (e.g., Ardabil) and Northern (Caspian Sea littoral) regions of Iran has been reported to be considerably high [age-standardized incidence rates (ASRs) > 20/100,000]. In contrast, the Southern provinces, including Khuzestan, Kerman, and Yazd, exhibit much lower rates, with ASRs < 10/100,000. Despite these disparities, the specific contributions of bacterial and host factors, as well as geographic and ethnic differences in the incidence of GC in Iran, remain unclear. Ardabil exhibits the highest incidence rates of GC, with ASRs of 51.8 per 100,000 for males and 24.9 per 100,000 for females, especially concerning cardia GC, in both Iran and Central Asia (12-15).

2. Objectives

In light of this, we assessed the expression levels of long intergenic non-protein coding RNA 659 (LINC00659-ENSG000022805), known for its oncogenic implications in colorectal cancer (CRC) (16), among GC patients in Ardabil to examine its potential as a diagnostic biomarker.

3. Methods

3.1. Study Cases

Forty-one tumor samples from GC patients, as well as 41 samples from corresponding adjacent non-cancerous tissues (ANCTs), were collected (n = 82) from GC patients who underwent endoscopy at Imam Khomeini Hospital of Ardabil from October 2017 to February 2020. The resection margin, defined as the distance from the tumor border to the adjacent tissue, was 1.5 to 2 cm. The examined cryopreserved samples were freshly sliced and stored in liquid nitrogen to maintain their morphological integrity until use. Tissue specimens were assessed via standard histopathological assessments. Histopathological assessments were conducted in accordance with the revised Sydney system (17). Additionally, Lauren's classification classification was employed to identify the histomorphological characteristics of the tumors, categorizing them as intestinal-type or diffuse-type adenocarcinomas, squamous cell carcinoma, and mucinous gastric carcinoma (18). Furthermore, the tumors were classified by their anatomical location based on the 10th Revision of the International Classification of Diseases, specifically C16.0 for cardia and C16.1 - C16.9 for non-cardia, which includes unspecified subsites overlapping and (https://apps.who.int/iris/handle/10665/42980). Patients subjected to radiation therapy, chemotherapy, or immunotherapy were not included. Informed consent was signed by GC patients. This study was approved approval under the ethical code of IR.ARUMS.REC.1396.160. All tissues were stored at -80°C.

3.2. RNA Extraction, cDNA Synthesis, and Real-time Reverse Transcriptase PCR

The TRIZOL Kit (Invitrogen) was used to separate total RNAs from the samples based on the manufacturer's protocol. The quantity and quality of the extracted RNAs were assessed using а NanoDrop2000c spectrophotometer (Thermo Fisher). The cDNA was synthesized with a Takara kit (TaKaRa, Dalian, China). A total of 1 µg of RNA was reverse transcribed in a final volume of 20 µL with random primers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to quantify lncRNA as an internal reference. Quantitative real-time PCR reactions were carried out with the SYBR Green Master Mix (Takara). A Rotor-Gene 6000 Corbett real-time PCR System was used to compare the relative IncRNA expression level between non-tumoral and tumoral samples. There was a non-template negative control for every run. The following gene-specific primers were used for LINC00659 and GAPDH: LINC00659 - forward /5'-ACCCTGAAGGACCATATCCA-3', LINC00659 - reverse /5'-GGCTCGGCTGTGTCTCAAG-3', GAPDH - forward /5'-TGCACCACCAACTGCTTA-3', and GAPDH - reverse /5'-GGATGCAGGGATGATGTTC-3'. Relative fold-change was calculated using the 2– $\Delta\Delta$ Ct value. Experiments were repeated in triplicate.

3.3. Statistical Analysis

Relative quantification of the target gene expression was calculated using a two-sided Pair-Wise Fixed Reallocation Randomization Test by Relative Quantification Software Tool (REST 2009) software. Fold change was determined to detect gene expression differences between tumor tissues and ANCTs. The chi-





square test (χ^2) was employed for assessing the correlation between LINC00659 gene expression and clinicopathological characteristics. P-values < 0.05 were considered significant.

4. Results

Our study examined LINC00659 expression levels in GC tissues compared with non-tumor tissues (n = 82) through real-time RT-PCR. The average age of cases was 66.02 ± 9.2 years (range, 42 to 83 years). Additionally, 74.3% of them were males. Furthermore, 63.4% of tumors were found in the cardia subsite, 9.8% in both the cardia and non-cardia subsites, and 26.8% in the non-cardia subsite. Histologically, 42.5% of them had the diffuse type, 42.5% had the intestinal type, and 15% had other GC types. For 25% of patients, there was a positive family history of GC (first or second degree). The LINC00659 relative expression level was not significantly different between tumor samples compared to controls [Fold change (mean \pm SE): 0.57 \pm 0.13, P = 0.33; Figure 1A].

The relative expression level was also not significantly different (between tumors vs. ANCTs) when the analysis was performed based on anatomical sites and histopathological types of the tumors. The fold change (mean \pm SE) was 0.57 \pm 0.32 and 0.41 \pm 0.18 for cardia and non-cardia subsites, respectively, and 0.46 \pm 0.24 and 0.63 \pm 0.16 for intestinal-type GC and diffusetype GC, respectively (Figure 1A and B). In contrast, we found a significant association between LINC00659 expression levels and tumor origin after classifying patients into up- or down-regulation groups (P = 0.01; Table 1; Figure 2). In the up-regulation (vs. downregulation) group, 38.5% (vs. 61.5%) of tumors were found in the cardia subsite, 18.2% (vs. 81.8%) in the non-cardia subsite, and 100% (vs. 0%) in both the cardia and noncardia subsites. According to histological characteristics, in the up-regulation (vs. downregulation) group, 41.2% (vs. 58.8%) had the diffuse type, 41.2% (vs. 58.8%) had the intestinal type, and 33.3% (vs. 66.7%) had other GC types. Such an association was not significant for other clinicopathological characteristics, such as age, pathology, gender, and family history of GC (P > 0.05).

5. Discussion

The emergence of high-throughput RNA sequencing (RNAseq) has led to the identification of thousands of unknown lncRNAs, whose improper expression is closely associated with cancer development and initiation. Dysregulation of lncRNAs is closely related to tumorigenesis, metastasis, diagnosis, or prognosis of GC. Recently, several lncRNA-associated GCs have been detected. Nonetheless, the underlying mechanisms regulating GC progression remain largely unknown. In the study by Wang et al., it was shown that LINC00659 levels were significantly elevated in GC. SP1 activated the up-regulation of LINC00659 in GC. There was an association between higher levels of LINC00659 and TNM stage, lymphatic metastasis, and poorer prognosis. Overexpression of LINC00659 also resulted in a reduction of AQP3, which was suppressed by miR-370 mimics. LINC00659 appears to act as a molecular sponge for miR-370, modulating AQP3 expression as a tumor promoter in GC. In an m6A-YTHDF2-dependent manner, LINC00659 upregulated JAK1 mRNA by facilitating ALKBH5 binding. The JAK1 axis was disrupted when ALKBH5 or LINC00659 were silenced. As IAK1 was up-regulated in GC, the JAK1/STAT3 pathway was activated (19).

In the study by Wang et al., it was shown that LINC00659 levels were clearly elevated in GC. SP1 activated the up-regulation of LINC00659 in GC. There was an association between higher levels of LINC00659

Variables	LINC00659 Up-Regulation	LINC00659 Down-Regulation	P-Value
Age			0.09
< 60	1 (12.5)	7 (87.5)	
≥60	13 (44.8)	16 (55.2)	
Sex			1
Female	10 (38.5)	16 (61.5)	
Male	3 (33.3)	6 (66.7)	
Tumor origin			0.01
Cardia	10 (38.5)	16 (61.5)	
Cardia and non-cardia	4 (100)	0(0)	
Non-cardia	2 (18.2)	9 (81.8)	
Pathology			0.94
Intestinal	7 (41.2)	10 (58.8)	
Diffuse	7 (41.2)	10 (58.8)	
Other	2 (33.3)	4 (66.7)	
Family history			0.85
Positive	4 (40)	6(60)	
Negative	11 (36.7)	19 (63.3)	

Table 1. Association Analysis Between Expression Levels of LINC00659 and Clinicopathological Characteristics in Gastric Cancer Patients from October 2017 to February 2020^{a, b}

^a Values are expressed as No. (%).

^b Up- and down-regulation of the gene have been defined based on the relative expression of the gene in malignant samples versus adjacent non-cancerous tissues.

and TNM stage, lymphatic metastasis, and poorer prognosis. Overexpression of LINC00659 also resulted in a reduction of AQP3, which was suppressed by miR-370 mimics. LINC00659 appears to act as a molecular sponge for miR-370, modulating AQP3 expression as a tumor promoter in GC (19). In an m6A-YTHDF2dependent manner, LINC00659 upregulated JAK1 mRNA by facilitating ALKBH5 binding. The JAK1 axis was disrupted when ALKBH5 or LINC00659 were silenced. As JAK1 was up-regulated in GC, the JAK1/STAT3 pathway was activated (20). LINC00659 derived from cancerassociated fibroblasts (CAFs) promotes CRC cell proliferation, invasion, and migration via the miR-342-3p/ANXA2 axis (21). Zhang et al. revealed that LINC00659 binds directly to the polypyrimidine tract-binding protein (PTBP1). By knocking down LINC00659 expression, PTBP1 binding was inhibited under H. pylori infection. LINC00659 knockdown reduced gastric epithelial cell senescence induced by *H. pylori* infection. It also suppressed interleukin-6 and IL-8 secretion through NF-κB p65 phosphorylation reduction (22). Sheng et al. indicated that LINC00659 expression levels were markedly up-regulated in GC patients. Elevated levels of LINC00659 were associated with advanced tumor stage and unfavorable prognosis for GC patients. Also, up-regulated LINC00659 expression could promote GC cell invasion. Bioinformatics studies indicated IQ motif containing GTPase activating protein 3 and matrix metalloproteinase 15 as possible downstream targets of LINC00659 associated with tumor metastasis. However, the exact underlying mechanism needs further exploration (23). Sheng et al. reported an expression level of LINC00659 in GC, which can be due to the promotion of cell invasion and regulation of cell proliferation. SUZ12 is a transcription factor and regulates LINC00659. Also, LINC00659 regulates cell cycle and GC invasion through an increase in SUZ12 expression (23). LINC00659 up-regulation was linked with poor survival in CRC patients. LINC00659 was found to have a significant co-expression with cyclerelated genes in CRC. Silencing of LINC00659 expression caused cell growth inhibition and induced apoptosis, probably through suppression of AKT-PI3K signaling in colon cancer (16). On the contrary, in our study, although LINC00659 was down-regulated in more GC samples than controls (expression ratio = 0.57), the difference did not reach statistical significance. After classifying patients into up- or down-regulation groups, a significant association was found between LINC00659 expression levels and tumor site (P < 0.05). No significant association between LINC00659 expression levels and GC risk is probably due to the sample size, which might not have been sufficient for the assessment. The differences between our findings and two recent studies can be due to the fact that many IncRNAs display both tumor suppressive and oncogenic





functions (24). Human populations are also genetically diverse, and SNPs in lncRNAs largely influence expression (11). In addition, most samples originated from the cardia subsite (63.4%), which are largely different from non-cardia samples based on tumor features, distinct etiologies, and biological behaviors (25). Thus, it can be expected that the mechanisms of lncRNA function in the process of carcinogenesis will be different. Further research involving a larger sample size that encompasses diverse geographic and ethnic groups within Iran is essential to enhance the validity of the findings. This will facilitate a deeper understanding of the functional mechanisms of LINC00659 in GC and elucidate its impact on cellular pathways and tumorigenesis.

Acknowledgements

We would like to thank all patients who participated in this study and the clinical staff and research nurses of Aras Clinic at Imam Khomeini Hospital, particularly Farideh Feizi and Robab Fouladi.

Footnotes

Authors' Contribution: S. L. N. provided direction in the preparation of the manuscript; E. A. performed the experiments; E. A. and E. A. wrote the first draft of manuscript; V. K. O. and E. A. analyzed data; S. L. N., A. Y., and S. Z. discussed and revised the manuscript; A. Y. and E. A. managed the references; S. L. N. approved the version to be published.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: This study was approved under the ethical approval code of IR.ARUMS.REC.1396.160.

Funding/Support: This work was supported by the Research Council of the University of Mohaghegh Ardabili. The supporter had no role in study design, data collection and analysis, decision to publish, or

preparation of the manuscript. There was no additional external funding received for this study.

Informed Consent: Informed consent for participation in the study was given by each subject in writing.

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;**68**(6):394-424. [PubMed ID: 30207593]. https://doi.org/10.3322/caac.21492.
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014;**513**(7517):202-9. [PubMed ID: 25079317]. [PubMed Central ID: PMC4170219]. https://doi.org/10.1038/nature13480.
- Abdi E, Latifi-Navid S, Abdi F, Taherian-Esfahani Z. Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers. *Expert Rev Mol Diagn*. 2020;20(11):1121-38. [PubMed ID: 33103502]. https://doi.org/10.1080/14737159.2020.1842199.
- Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. *Nat Genet*. 2015;47(3):199-208. [PubMed ID: 25599403]. [PubMed Central ID: PMC4417758]. https://doi.org/10.1038/ng.3192.
- Qian Y, Shi L, Luo Z. Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy. Front Med (Lausanne). 2020;7:612393. [PubMed ID: 33330574]. [PubMed Central ID: PMC7734181]. https://doi.org/10.3389/fmed.2020.612393.
- Hu QY, Zhao ZY, Li SQ, Li L, Li GK. A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer. *Mol Clin Oncol.* 2017;6(6):846-52. [PubMed ID: 28588775]. [PubMed Central ID: PMC5451877]. https://doi.org/10.3892/mco.2017.1227.
- Jiang C, Li Y, Zhao Z, Lu J, Chen H, Ding N, et al. Identifying and functionally characterizing tissue-specific and ubiquitously expressed human lncRNAs. *Oncotarget.* 2016;7(6):7120-33. [PubMed ID: 26760768]. [PubMed Central ID: PMC4872773]. https://doi.org/10.18632/oncotarget.6859.
- Raei N, Safaralizadeh R, Hesseinpourfeizi M, Yazdanbod A, Pourfarzi F, Latifi-Navid S. Crosstalk between lncRNAs and miRNAs in gastrointestinal cancer drug resistance. *Life Sci.* 2021;284:119933. [PubMed ID: 34508759]. https://doi.org/10.1016/j.lfs.2021.119933.
- Abdi E, Latifi-Navid S. Emerging long noncoding RNA polymorphisms as novel predictors of survival in cancer. *Pathol Res Pract.* 2022;239:154165. [PubMed ID: 36257235]. https://doi.org/10.1016/j.prp.2022.154165.
- Abdi E, Latifi-Navid S, Zahri S, Kholghi-Oskooei V, Mostafaiy B, Yazdanbod A, et al. SNP-SNP interactions of oncogenic long noncoding RNAs HOTAIR and HOTTIP on gastric cancer susceptibility. *Sci Rep.* 2020;**10**(1):16763. [PubMed ID: 33028884]. [PubMed Central ID: PMC7541458]. https://doi.org/10.1038/s41598-020-73682-0.
- Minotti L, Agnoletto C, Baldassari F, Corra F, Volinia S. SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies? *High Throughput*. 2018;7(4). [PubMed ID: 30453571]. [PubMed Central ID: PMC6306726]. https://doi.org/10.3390/ht7040034.
- Babaei M, Pourfarzi F, Yazdanbod A, Chiniforush MM, Derakhshan MH, Mousavi SM, et al. Gastric cancer in Ardabil, Iran–a review and update on cancer registry data. *Asian Pac J Cancer Prev.* 2010;11(3):595-9. [PubMed ID: 21039022].

- Eskandar H, Hossein SS, Rahim M, Jalal H, Mehrdad A, Rajabi T. Clinical profile of gastric cancer in Khuzestan, southwest of Iran. World J Gastroenterol. 2006;12(30):4832-5. [PubMed ID: 16937464]. [PubMed Central ID: PMC4087616]. https://doi.org/10.3748/wjg.v12.i30.4832.
- Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. *Arch Iran Med.* 2009;**12**(6):576-83. [PubMed ID: 19877751].
- Mohebbi M, Mahmoodi M, Wolfe R, Nourijelyani K, Mohammad K, Zeraati H, et al. Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: spatial analysis of cancer registry data. *BMC Cancer*. 2008;8:137. [PubMed ID: 18479519]. [PubMed Central ID: PMC2397428]. https://doi.org/10.1186/1471-2407-8-137.
- Tsai KW, Lo YH, Liu H, Yeh CY, Chen YZ, Hsu CW, et al. Linc00659, a long noncoding RNA, acts as novel oncogene in regulating cancer cell growth in colorectal cancer. *Mol Cancer*. 2018;17(1):72. [PubMed ID: 29523145]. [PubMed Central ID: PMC5845323]. https://doi.org/10.1186/s12943-018-0821-1.
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol.* 1996;**20**(10):1161-81. [PubMed ID: 8827022]. https://doi.org/10.1097/00000478-199610000-00001.
- Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. *Acta Pathol Microbiol Scand.* 1965;64:31-49. [PubMed ID: 14320675]. https://doi.org/10.1111/apm.1965.64.1.31.
- Wang Y, Guo Y, Zhuang T, Xu T, Ji M. SPI-Induced Upregulation of IncRNA LINC00659 Promotes Tumour Progression in Gastric Cancer by Regulating miR-370/AQP3 Axis. Front Endocrinol (Lausanne). 2022;13:936037. [PubMed ID: 35957833]. [PubMed Central ID: PMC9361049]. https://doi.org/10.3389/fendo.2022.936037.
- Fang Y, Wu X, Gu Y, Shi R, Yu T, Pan Y, et al. LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m(6) A-YTHDF2-dependent manner. *Clin Transl Med.* 2023;**13**(3). e1205. [PubMed ID: 36864711]. [PubMed Central ID: PMC9982078]. https://doi.org/10.1002/ctm2.1205.
- Zhou L, Li J, Tang Y, Yang M. Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis. *J Transl Med*. 2021;**19**(1):8.
 [PubMed ID: 33407563]. [PubMed Central ID: PMC7789760]. https://doi.org/10.1186/s12967-020-02648-7.
- Zhang J, Zhang Z, Shen D. Upregulated LncRNA-LINC00659 expression by H. pylori infection promoted the progression of gastritis to cancer by regulating PTBP1 expression. *Indian J Pathol Microbiol.* 2024;67(3):510-7. [PubMed ID: 38394397]. https://doi.org/10.4103/ijpm.ijpm_48_23.
- Sheng Y, Han C, Yang Y, Wang J, Gu Y, Li W, et al. Correlation between LncRNA-LINC00659 and clinical prognosis in gastric cancer and study on its biological mechanism. *J Cell Mol Med*. 2020;**24**(24):14467-80. [PubMed ID: 33145980]. [PubMed Central ID: PMC7754062]. https://doi.org/10.1111/jcmm.16069.
- Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell. 2019;179(5):1033-55. [PubMed ID: 31730848]. [PubMed Central ID: PMC7347159]. https://doi.org/10.1016/j.cell.2019.10.017.
- 25. Abdi E, Latifi-Navid S, Zahri S, Yazdanbod A, Pourfarzi F. Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. *Cancer Med.* 2019;8(13):6114-26. [PubMed ID: 31448582]. [PubMed Central ID: PMC6792520]. https://doi.org/10.1002/cam4.2497.